Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Kidney International

Topics

Medicine

Epidemiology

Pathology

Internal Medicine

Endocrinology

Show all topics

DOI

10.1038/ki.2013.356

License

CC-BY-NC-ND

Other Formats

PDF